These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Efficacy and safety of Gemogenovatucel-T (Vigil) immunotherapy for advanced ovarian carcinoma: A systematic review and meta-analysis of randomized controlled trials. Zhang Y; Zhang L; Zhao Y; Wang S; Feng L Front Oncol; 2022; 12():945867. PubMed ID: 36338747 [TBL] [Abstract][Full Text] [Related]
6. ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer. Rocconi RP; Stanbery L; Tang M; Madeira da Silva L; Walter A; Monk BJ; Herzog TJ; Coleman RL; Manning L; Wallraven G; Horvath S; Bognar E; Senzer N; Brun S; Nemunaitis J Commun Med (Lond); 2022; 2():106. PubMed ID: 36051466 [TBL] [Abstract][Full Text] [Related]
7. Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer. Barve M; Aaron P; Manning L; Bognar E; Wallraven G; Horvath S; Stanbery L; Nemunaitis J Clin Med Insights Oncol; 2022; 16():11795549221110501. PubMed ID: 35957960 [TBL] [Abstract][Full Text] [Related]
8. Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer. Oh J; Barve M; Matthews CM; Koon EC; Heffernan TP; Fine B; Grosen E; Bergman MK; Fleming EL; DeMars LR; West L; Spitz DL; Goodman H; Hancock KC; Wallraven G; Kumar P; Bognar E; Manning L; Pappen BO; Adams N; Senzer N; Nemunaitis J Gynecol Oncol; 2016 Dec; 143(3):504-510. PubMed ID: 27678295 [TBL] [Abstract][Full Text] [Related]
9. Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer. Rocconi RP; Stanbery L; Madeira da Silva L; Barrington RA; Aaron P; Manning L; Horvath S; Wallraven G; Bognar E; Walter A; Nemunaitis J Vaccines (Basel); 2021 Aug; 9(8):. PubMed ID: 34452019 [TBL] [Abstract][Full Text] [Related]
16. Effect of PARP Inhibitors as Maintenance Treatment on Restricted Mean Survival Time in Platinum-Sensitive Recurrent Ovarian Cancer: A Systematic Review and Meta-analysis. Kaneko M Ann Pharmacother; 2022 Jan; 56(1):27-34. PubMed ID: 33926263 [TBL] [Abstract][Full Text] [Related]
17. Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas. Yi T; Feng Y; Sundaram R; Tie Y; Zheng H; Qian Y; You D; Yi T; Wang P; Zhao X Int J Cancer; 2019 Sep; 145(5):1209-1220. PubMed ID: 30666631 [TBL] [Abstract][Full Text] [Related]